Pure Global
NCT06381141

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Cullinan Therapeutics Inc.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
CLN-619
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cullinan Therapeutics Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2024
End date
Mar 01, 2027
Enrollment
30 participants
Primary outcome

Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs),Changes in Eastern Cooperative Oncology Group (ECOG) performance,Incidence of Dose-Limiting toxicity (DLTs),Best Overall Response (BOR) per patient,Overall Response Rate (ORR),Duration of Response (DoR),Clinical Benefit Rate (CBR),Progression Free Survival (PFS),Overall Survival (OS)

Summary

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619
 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06381141
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06381141 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cullinan Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.